MYC Knockout DMS273 Cell Line

The choice depends on whether you are studying MYC (c-Myc)'s role as the principal proliferative transcription factor in small cell lung cancer or its functions as a global amplifier of transcription. The Knockout line is the standard tool for asking whether MYC is required for SCLC proliferation — DMS 273 is a small cell lung cancer (SCLC) cell line where MYC amplification and overexpression drive aggressive proliferation. Overexpression is useful for studying MYC gain-of-function in other contexts, but DMS 273 already has MYC amplification. Important consideration: MYC knockout may be lethal or growth-suppressive in MYC-dependent cancers like SCLC — characterize growth and viability phenotypes carefully. The MYC-null cells that survive may represent a selected population. For SCLC research, the EDITGENE MYC Knockout in DMS 273 is highly relevant — SCLC is a MYC-family-driven cancer (MYC, MYCN, MYCL amplifications define molecular subtypes), and MYC loss in DMS 273 enables study of MYC-addicted SCLC biology. Rescue with wild-type or transactivation-deficient (W135E) MYC enables structure-function studies. The knockout is a critical specificity control for MYC-targeted therapeutics (OMOMYC peptide, MYC-MAX interaction inhibitors, BET inhibitors that downregulate MYC) in SCLC drug development.

Primary applications: • SCLC proliferation: cell growth kinetics and clonogenicity given MYC-addiction of small cell lung cancer. • MYC target gene expression: RNA-seq analysis of MYC target genes (E-box-containing genes; ribosomal biogenesis, metabolic genes) in MYC-null versus rescued context. • BET inhibitor mechanism: JQ1, OTX015, and other BET inhibitors downregulate MYC — assessment of BET inhibitor effects requires comparison with MYC-null controls. • MYC-targeted drug specificity: critical genetic control for OMOMYC peptide and MYC-MAX interaction inhibitors in SCLC drug development. EDITGENE recommends this model for researchers investigating MYC-addicted SCLC biology and MYC-targeted therapeutic mechanisms.

Yes, with viability considerations for MYC-addicted SCLC: • Construct design: use a codon-modified MYC sequence with a small C- or N-terminal tag (FLAG, HA). MYC has N-terminal transactivation domain (TAD with MB1/MB2/MB3 boxes), central regulatory region, and C-terminal bHLH-LZ (DNA binding and MAX dimerization) — preserve all elements. • Transactivation-deficient rescue: W135E mutation in MB2 abolishes transactivation and is the standard control. • MAX-interaction-deficient rescue: bHLH-LZ mutations disrupt MAX dimerization, abolishing DNA binding without affecting transactivation domain function. • Viability considerations: complete MYC rescue should restore SCLC proliferation; partial rescue with structure-function variants may show varied effects on growth. • Functional readout: rescue should restore MYC target gene expression and proliferative capacity. DMS 273 is an SCLC cell line; transduction with lentivirus is supported with standard SCLC optimization.